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Background and aims: An abdominal aortic aneurysm (AAA) is part of the atherosclerotic spectrum of
diseases. The disease is hallmarked by a comprehensive localized inﬂammatory response with striking
IL-6 hyperexpression. IL-6 is a multifaceted cytokine that, depending on the context, acts as a pro- or
anti-inﬂammatory factor. In this study, we explore a putative role for IL-6 in AAA disease.
Methods: ELISA’s, Western blot analysis, real time PCR and array analysis were used to investigate IL-6
expression and signaling in aneurysm wall samples from patients undergoing elective AAA repair. A
role for IL-6 in AAA disease was tested through IL-6 neutralization experiments (neutralizing antibody) in
the elastase model of AAA disease.
Results: We conﬁrmed an extreme disparity in aortic wall IL-6 content between AAA and atherosclerotic
disease (median [5the95th percentile] aortic wall IL-6 content: 281.6 [0.0e1820.8] (AAA) vs. 1.9 [0.0
e37.8] mg/g protein (atherosclerotic aorta), (p < 0.001). Array analysis followed by pathway analysis
showed that IL-6 hyper-expression is followed by increased IL-6 signaling (p < 0.000039), an observation
conﬁrmed by higher aneurysm wall pSTAT3 levels, and SOCS1 and SOCS3 mRNA expression, (p < 0.018).
Remarkably, preventive IL-6 neutralization i.e. treatment started one day prior to the elastase-induction
resulted in >40% 7-day mortality due to aortic rupture. In contrast, delayed IL-6 neutralization (i.e.
neutralization started at day 4 after elastase induction) did not result in ruptures, and quenched AAA
growth (p < 0.021).
Conclusions: AAA disease is characterized by increased IL-6 signaling. In the context of the elastase
model of AAA disease, IL-6 appears a multi-faceted factor, protective upon acute injury, but negatively
involved in the perpetuation of the disease process.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
An abdominal aortic aneurysm (AAA) is common pathology that
is considered part of the atherosclerotic spectrum of diseases [1].
Current clinical management fully relies on surgical repair of larger
(viz. maximum diameter 55 mm or more) AAA. Yet, while tradi-
tional open repair comes with signiﬁcant perioperative morbidityGAPDH, Glyceraldehyde-3-
, Phosphate buffered saline;
tor of transcription 3; SOCS1,
ors of cytokine signaling 3.
6-R, PO Box 9600, 2300 RC,
an).
r Ireland Ltd. This is an open accesand mortality, endovascular therapy requires life-long follow up
and the cost-effectiveness of endovascular repair is being chal-
lenged [2]. It has thus been pointed out that pharmaceutical ther-
apy quenching or halting aneurysm growth holds many promises,
both from the patient’s point of view as from the socio-economical
point of view [3].
It is generally assumed that AAA growth is driven by a
comprehensive inﬂammatory response, and consequently that
interference with the inﬂammatory response will alleviate aneu-
rysm progression. The validity of this approach has been well
shown in numerous animal studies, but thus far clinical in-
terventions failed [4e6]; a conclusion pointing to incomplete un-
derstanding of the inﬂammatory aspects of AAA disease.
The inﬂammatory footprint of AAA is complex and includes both
components of an acute inﬂammatory response such as neutrophilss article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Study scheme of the elastase model. Arrows (↓) depict anti IL-6 injections.
Mouse were sacriﬁced at day 14 (y) and the aorta harvested.
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cells, tertiary follicles) [3]. On themolecular level the disease is best
deﬁned as a general pro-inﬂammatory response with compre-
hensive and intense upregulation of pro-inﬂammatory cytokines
and chemokines, including notably high IL-6 levels [7]. In fact, it has
been reported that aortic wall IL-6 protein levels in AAA exceed
those in advanced atherosclerotic disease by several 100-fold,
implicating IL-6 as a potential critical inﬂammatory factor in AAA
disease [7]. This notion is supported by robust genetic evidence
linking a polymorphism in the IL-6 gene promoter (IL-6-572G > C)
to AAA disease (reported odds ratio: 6.00) [8].
IL-6 has long been considered a pro-inﬂammatory cytokine and,
through its pro-inﬂammatory activities, a culprit in the develop-
ment and complications of atherosclerotic disease [9,10]. Yet, it is
now becoming apparent that IL-6 is versatile multifunctional (Ja-
nus-like) cytokine with functions that extend beyond that of a pro-
inﬂammatory cytokine; and include coordination of immune and
acute responses, regulation of hematopoiesis [9], as well as roles in
tissue protection and regeneration [11,12]. Consequently, the
biology of IL-6 is complex and, depending on the context IL-6 may
exert protective activities as well as detrimental actions [13].
In light of these observations, we considered an evaluation of a
putative role for IL-6 in AAA relevant. To this purpose, we evaluated
the IL-6 signaling pathways in human AAA disease, and tested a
role for IL-6 in the initiation and progression of AAA in the murine
elastase model, an established model of AAA disease.
2. Patients and methods
2.1. Human samples
The investigation conforms to the principles outlined in the
Declaration of Helsinki (2013). Sample collection and handling
were performed in accordance with the guidelines of the medical
ethical committee of the Leiden University Medical Center and
University Medical Center Utrecht. Control infra renal aorta was
selected from a tissue bank of aortic wall patches that were ob-
tained during kidney procurement for organ donation. Character-
istics of these samples have been described elsewhere [14].
Controls were age matched and only samples displaying athero-
sclerotic lesions were included.
Aneurysm wall samples (anterior-lateral wall) were collected
during elective surgery for asymptomatic AAA (55 mm or larger).
Wall samples were divided into two parts. One half was immedi-
ately snap-frozen in CO2-cooled iso-pentane or liquid N2 and stored
at 80 C for later analysis. The other half was ﬁxed in 4% formalin
for 24 h followed by decalciﬁcation (Kristenssen solution). Next,
these segments were parafﬁn embedded and 4 mm sections were
processed into slices.
A further analysis of the effects of doxycycline on SOCS-1 and 3
signaling was performed on cDNA samples from an earlier doxy-
cycline intervention trial [15].
2.2. Elastase model
All animal experiments were approved by the Leiden University
Medical Center animal welfare committee, and performed in
compliance with the Dutch governmental guidelines.
IL-6 activity was quenched through repeated doses (4 mg/kg) of
an IL-6 neutralizing antibody (MAB406, R&D systems, Abingdon,
UK). This antibody and dosing scheme was earlier shown to fully
quench IL-1-induced hepatic CRP expression (a process mediated
by IL-6 and STAT3 signaling) in a pilot study using human CRP
transgenic mice [16].
Eight-to-ten week old, male, wild-type (WT; C57BL/6) micewere obtained from Charles River (Chatillon-sur-Chalaronne,
France). Animals were housed in a temperature and humidity-
controlled room on a 12:12-h lightedark cycle with ad libitum
access to water and normal chow diet.
Infra renal aneurysms were created via incubation of the iso-
lated terminal aorta segment with type I porcine pancreatic elas-
tase (4.5 U/mL; Sigma-Aldrich, Zwijndrecht, the Netherlands) as
previously described [17]. Brieﬂy, the aorta was exposed and a
catheter positioned at the iliac bifurcation. The catheter was
removed after elastase infusion, and the abdomen closed after
hemostatic control. Mice were given 0.1 mg/kg/12 h buprenor-
phine, allowed to recover with free access to food and water.
A role for IL-6 in AAA initiation and progression was assessed
through repeated anti-IL-6 injections (IP) starting at the day before
elastase infusion (day -1), followed by injections on day 3, day 7 and
day 11 (n ¼ 9) (Fig. 1). Control animals (n ¼ 9) received parallel IP
injections with PBS.
There were a high number of unexpected deaths in the 24 h
following aneurysm induction in the treatment arm. To that endwe
set up a second experiment (n¼ 8) inwhich IL-6 neutralizationwas
delayed, i.e. therapy was initiated on day 3 after elastin treatment
the infusion.
Aneurysm formation and growth in all groups was assessed by
ultrasound (Vevo 770 Imaging system using RMV 704 micro-
visualization scan head (Visualsonics, CA)). The maximum axial
diameter of the aorta was measured at day -1 (one day prior to
elastase infusion), day 7 and 14. Mice were sacriﬁced after the ﬁnal
aneurysm reading and their aorta was removed, formalin ﬁxed and
parafﬁn embedded.2.3. Aneurysm wall IL-6 content
Aorta wall IL-6 protein levels were determined in 238 AAA
samples from the Aneurysm-Express Biobank [18] Twenty six
atherosclerotic aortic wall samples served as control. IL-6 content
was measured through Luminexmulti-analyte proﬁling technology
[19,20], using a bio-plex system (Bio-Rad, USA), and the content
normalized on basis of total protein content (BCA protein mea-
surement method (Pierce Biotechnology, USA)). Inter-assay coefﬁ-
cient of variation was <10%.2.4. Immunohistochemistry
Human (n ¼ 10 AAA samples and n ¼ 10 control atherosclerotic
aorta samples) and murine tissue sections were deparafﬁnized and
incubated overnight at room temperature with the primary anti-
body diluted in PBS, 1% BSA, using the following primary antibodies
for the human studies: IL-6 (Santa Cruz Biotechnology, USA), IL-6R
or CD126 (Abcam, UK) and pSTAT3 (Abcam, UK). Envision mouse or
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[15].
Murine sections were incubated with CD45 (BD Pharmingen,
USA), MAC3 (BD Pharmingen,USA), MMP9 (Santa Cruz Biotech-
nology, USA) and Smooth Muscle Alpha Actin (DAKO, Denmark).
Further sections were stained with Sirius Red for collagen and
Weigert’s elastin stain to visualize elastic lamina. Eight slides per
animal were used per staining for analysis and only moderate or
strongly reactive cells were counted as positive. The slides were
blindly evaluated. A mean value for positive staining cells in the
eight sections was calculated for each animal.
2.5. Microarrays
RNA extraction was performed from full thickness aortic wall
samples from 31 AAA patients (mean age 69.5 yrs mean diameter
62.3 ± 12.1 mm) and 9 control samples (infra renal aorta obtained
during kidney procurement for donation).
RNA from aneurysmwall was labeled and hybridized to Illumina
HumanHT-12 v4 BeadChips. Arrays were scanned with an Illumina
iScan microarray scanner. Bead level data preprocessing was done
in Illumina GenomeStudio.
2.6. Analysis of array data
Quantile normalization and background reduction were per-
formed according to standard procedures in the Illumina
GenomeStudio software.
Association of genome-wide expression data with AAA pheno-
type revealed 11486 transcripts with p < 0.05. These differentially
expressed transcripts were used as an input for pathway analysis
through Ingenuity Pathway Analysis suite (http://www.ingenuity.
com, accessed 2016). Levels of signiﬁcance were determined us-
ing Fisher’s exact tests implemented in the software.
2.7. Western blot analysis
Samples for Western blot were homogenized and lyzed in the
following buffer: 150 mM NaCl, 50 mM Tris (pH 8,0), 1.0% Triton X-
100, 0.1% SDS, 0.5% sodium deoxycholate, 10 mM orthovanadate
and Protease inhibitor cocktail (Roche, The Netherlands), and
Western blot was performed as previously described [14], using the
following antibodies: pSTAT3 (GeneTex, The Netherlands), STAT3
(Santa Cruz Biotechnology, USA) and alpha actin (Abcam, Cam-
bridge, UK) for normalization. Donkey anti-rabbit IgG-HRP (Santa
Cruz Biotechnology, USA) was used as the secondary antibody.
Spots were visualized and quantiﬁed using the Super Signal West
Dura Extended Duration Substrate (Pierce Biotechnology, Ger-
many), and the luminescent imageworkstation (Roche Diagnostics)
with labworks 4.6 software [15].
2.8. Semi quantitative RealTime PCR analysis
IL-6, IL-6R (CD126), SOCS1 and SOCS3 mRNA expression was
quantiﬁed by semi quantitative RT, according to manufacturer’s
instructions in n ¼ 12 AAA samples and n ¼ 16 control athero-
sclerotic aorta samples. cDNA was prepared by using a Promega kit
for RT-PCR. Semi quantitative RNA analysis was performed using
the Taqman system for the determination of mRNA expression, we
used the established primer/probe sets (Life technologies, USA; IL-
6: Hs00985641_m1; IL6r: Hs01075666_m1; SOCS1:
Hs00705164_s1; SOCS3: Hs02330328_s1 and GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase)), the mastermix (Eurogentec,
Belgium) and the ABI-7700 system (Life Technologies, USA), as
previously described. GAPDH (Life Technologies, USA) was used fornormalization [15].
2.9. Statistical analysis
An ANOVA test was performed to explore the difference be-
tween human normal aortic and the aneurysm samples. Subse-
quently an unpaired t-test was performed. Non-normally
distributed data were log-transformed.
To evaluate the statistical signiﬁcant difference between the
mice treated for 15 days with anti-IL-6, mice treated for 10 days and
the controls were evaluated with a Kruskal-Wallis ANOVA test. All
parameters considered statistically signiﬁcant (p < 0.05) were
hereafter evaluated pair-wise with the Mann-Whitney U test.
Aneurysm formation in the elastase models was evaluated by the
Chi square test. All values are shown asmean (SD) or asmedian [5th
95th percentiles]. Probability values of p < 0.05 were considered
statistically signiﬁcant. The analyses were performed using SPSS
23.0 (IBM, Amsterdam, the Netherlands).
3. Results
3.1. Elevated IL-6 expression and pathway activation in aortic
aneurysm walls
The majority of studies on AAA wall cytokine proﬁles indicate
abundant IL-6 protein expression, yet the current literature is not
fully consistent. We therefore ﬁrst validated previous reports [7,21]
of prominent aortic wall IL-6 mRNA expression and elevated IL-6
protein levels in samples from the Aneurysm-Express Biobank.
This analysis conﬁrmed ample IL-6 mRNA expression (p < 0.001,
Fig. 2A), and sharply increased IL-6 protein levels in AAA wall
samples (aortic wall IL-6 content in AAA: 281.6 [0.0e1820.8] mg/g
protein vs.1.9 [0.0e37.8] mg/g protein median [5the95th percentile]
in atherosclerotic controls; p < 0.001, Fig. 2B).
IL-6 signaling is thought to occur via two distinct pathways.
Firstly, through the classic signaling route involving the IL-6 re-
ceptor (CD126)/GP-130 (CD130) receptor complex, and secondly via
a trans-signaling route that involves signaling through the GP-130
(CD130)/soluble-IL-6 receptor (sIL-6r) [9,12] complex. Signaling via
this later route is thought to activate the non-classical signaling
route [21]. While GP-130 is ubiquitously expressed, expression of
the IL-6 receptor is thought be more restricted. ELISA showed
abundant sIL-6r in AAA and control wall samples (Fig. 2D). Semi-
quantitative RealTime PCR for IL-6r mRNA showed increased
expression in AAA versus atherosclerotic aortic controls (p < 0.01).
Immunohistochemical evaluation for the aneurysm wall showed
diffuse expression IL-6r expression in mesenchymal cells and
subpopulations of lymphocytes in the adventitial inﬁltrates (con-
clusions based on cellular morphology). IL-6r expression in the
atherosclerotic controls was limited to the intimal layer (Fig. 2E).
Signaling through both the classical and non-classical route in-
volves phosphorylation of the STAT-3 transcription factor, and in-
duction of suppressor of cytokine signaling (SOCS) -1 and 3
expression. Ingenuity-based transcriptomics analysis shows upre-
gulation of IL-6 signaling pathway in AAA disease (canonical IL-6
pathway: p < 0.000039). More detailed analysis of the signaling
networks indicated selective activation of the JAK-STAT signaling
cascade but not of the RAS mediated ERK1/2 route (Fig. 3). Western
blot analysis conﬁrmed the array data and showed increased STAT3
phosphorylation in AAA (Fig. 4A, p < 0.018). SOCS1 and 3 mRNA
expression was higher in AAA wall samples than in controls
(p < 0.003, Fig. 4B). Immunohistochemistry for phosphor-STAT3
indicates that IL-6 signaling in AAA and atherosclerotic controls
mainly occurs in macrophages and smooth muscle cells (Fig. 4C).
The tetracycline analogue doxycycline has broad anti-
Fig. 2. Aortic wall IL-6 expression. (A) Aortic wall IL-6mRNA expression relative to the house keeping gene GAPDH, in atherosclerotic controls and AAA, *p < 0.001. (B) Normalized
aortic wall IL-6 protein content (ng/ml protein), *p < 0.001. (C) IL-6 localization in the human aneurysm wall. IL-6 is broadly expressed in lymphocytes, macrophages as well as
mesenchymal cells. Overview 40X, details 200X. (D) Similar aortic wall soluble IL-6 receptor protein content (ng/mg protein) in AAA and atherosclerotic controls. p ¼ ns. (E) IL-6
receptor (CD126) expression in AAA and atherosclerotic controls. CD126 expression in control aorta is limited to the intimal layer, whereas diffuse but selective expression
(subpopulations of lymphocytes, macrophages and mesenchymal cells) is observed in AAA tissue. Overview 40X, details 200X).
Fig. 3. IL-6 signaling pathways in AAA disease (Ingenuity Pathway Analysis). Speciﬁc upregulation of STAT3 mediated IL6 signaling but not of the RAS-ERK1/2 axis in AAA disease
(Ingenuity Pathway Analysis).
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IL-6 [15]. Paradoxically, a clinical trial concluded that doxycycline
accelerates aneurysm growth [5]. We hypothesized that this effect
may (partially) relate to suppression of SOCS expression.Comparison of SOCS-1 and 3mRNA expression in AAAwall samples
from patients that did and did not receive doxycycline treatment
showed that doxycycline treatment reduces AAA wall SOCS-1
mRNA expression (Fig. 4B, p < 0.037).
Fig. 4. Enhanced IL-6 signaling in AAA disease. (A) Similar aortic wall STAT3 but increased phosphorylated STAT3 (pSTAT3) content (Western blot analysis) in AAA tissue. Levels
normalized on a-actin content. (STAT3 (p ¼ ns) and *pSTAT3 (p < 0.030)). (B) Left bars: increased SOCS-1 and -3mRNA expression in AAA tissue, *p respectively <0.0008 and 0.0035).
Right bars: reduced aortic wall SOCS-1 mRNA expression after doxycycline therapy. (C) Phospho-STAT3 distribution in AAA tissue, showing IL-6 signaling in macrophages and
mesenchymal cells.
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murine elastase model of AAA disease through quenching IL-6 by
means of a validated IL-6 neutralizing antibody (Fig. 1). Unexpect-
edly, preventive IL-6 neutralization (i.e. therapy started at the day
prior to the elastase infusion) resulted in a >40% 7-day mortality
(Fig. 5A). Further evaluation showed that this mortality was due to
aortic rupture (Fig. 5A and B). No deaths or ruptures were observed
in the control group. In the surviving mice, preventive anti-IL-6
treatment did not inﬂuence the number of aneurysms formed
(>50% increase in aorta baseline diameter, p > 0.05) (Fig. 5C).
The observed detrimental effects of IL-6 neutralization may
relate to a possible protective role for IL-6 in the context of acute
injury [13]. We therefore performed a second series of experiments
in which IL-6 neutralization was delayed until day 4 (antibody
treatment was started on the fourth day following elastase treat-
ment). Delayed IL-6 neutralization did not result in rupture,
moreover, the IL-6 neutralizing antibody reduced the AAA pro-
gression (Fig. 5C, anti-IL-6 (delayed), p < 0.03). Histological evalu-
ation on day 14 (Fig. 6) showed that IL-6 neutralization did not
inﬂuence aortic wall leukocyte, macrophages or MMP9 content nor
the number of elastin breaks and collagen content compared to
control animals (Data not shown).4. Discussion
The pathology of AAA is complex and poorly understood. On the
molecular level, the disease is best described as an intense, local-
ized comprehensive inﬂammatory response [22e24]. At this point,
it is still unclear which aspects of this inﬂammatory response are
causatively involved in the disease process, and which factors arefound by association [25]. Remarkably, while there is genetic evi-
dence for an association between IL-6 signaling [8] and AAA dis-
ease, and while IL-6 hyperexpression has been reported as a
discriminative feature of the disease [7,21,26], no studies to date
addressed a possible role for IL-6 in the disease. Results from this
study conﬁrm ample IL-6 expression and increased IL-6 signaling in
human AAA tissue. IL-6 neutralization experiments in a mouse
model of AAA disease suggest that the role of IL-6 could be pro-
tective in the context of aneurysm formation, but disadvantageous
in the context of AAA progression.
Genetic and observational associations imply a link between IL-
6 and AAA disease. A report by Smallwood and colleagues identiﬁes
a polymorphism in the IL-6 gene promoter as a rare independent
risk factor for AAA [8]. Moreover, a Mendelian randomization
approach found robust evidence for a causal link between the IL-6
receptor signaling pathway and AAA disease [27]. On the (aneu-
rysm) tissue level most, the majority, but not all studies report
increased IL-6 levels [23,28,29], and the aneurysm wall has been
identiﬁed as a relevant source of plasma IL-6 [30].
Given the lack of full consistency with regard to IL-6 hyper-
expression [23], we ﬁrst performed a validation experiment for our
previous ﬁndings in a patient cohort [18] that is distinct from our
earlier studies [7]. Results of this evaluation again showed an
extreme disparity in aortic wall IL-6 content in AAA and athero-
sclerotic aorta wall samples with median AAA IL-6 content being
more than 100-fold higher than in atherosclerotic controls.
Although IL-6 is generally considered a pro-inﬂammatory
cytokine and a key-regulator of the acute phase response, it is
now clear that the roles of IL-6 extend beyond its traditional
function in inﬂammation/infection, and also include regulation of
Fig. 5. IL-6 neutralization in the elastase model of AAA disease. (A) Survival curves of mice receiving preventive anti-IL-6 (i.e. anti-IL-6 was administered before the elastase
perfusion), and vehicle treated control mice. Day 0 is the day of the elastin infusion. Mice were all sacriﬁced on day 14. (B) Explanted aorta of one of the deceased mice that received
preventive anti-IL-6 treatment showing a conﬁned rupture (the array indicates the lumen of the aorta), and (right) an ultrasound showing a murine aneurysm. (C) Delayed anti-IL6
(therapy initiated at day 4 after elastase infusion) quenches AAA formation (p < 0.03). No effect was seen in the mice that survived whereas the preventive treatment resulted in
similar aortic growth as the controls (p > 0.05). (D) Ultrasound image showing an aortic aneurysm in the elastase model.
Fig. 6. Histological examples of the elastase model. Histological staining for collagen (sirius red, left) and macrophages (MAC3, right) for a control and aneurysmal aorta.
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regeneration [9,12]. These disparate roles are thought to reﬂect
different signaling routes: the classical IL-6 receptor route being
responsible for the anti-inﬂammatory/tissue regenerative activities
[13], and the non-classical, trans-signaling route via the soluble IL-6
receptor being responsible for the pro-inﬂammatory activities.
These observations characterize IL-6 as a Janus-like factor with the
net effect depending on the activities of the two distinct signaling
routes, and the cross-talk with other inﬂammatory mediators
[9,12,13].
IL-6 receptor (CD126), responsible for the classical signaling
route was diffusely expressed in the mesenchymal cell population
within the aneurysmwall as well as in subpopulation of leucocytes
within the tertiary follicles. This pattern was clear distinct from
aortic atherosclerotic disease in which the receptor was essentially
expressed in the atherosclerotic region in the intima. At this point
both signaling routes are thought to converge on STAT3 transcrip-
tion factor effector pathway, and on SOCS-1 and 3 expression
[31e33]. As such, elevated STAT3 phosphorylation, and increased
SOCS-1 and 3 expression in AAA show that the increased IL-6 levels
in AAA disease are followed by augmented IL-6 signaling. Yet, this
data doesn’t allow for distinction between signaling via the tissue
protective (classical) route or via the pro-inﬂammatory (non-clas-
sical) signaling route.
We therefore decided for an experimental approach and tested
whether quenching of IL-6 via a neutralizing antibody inﬂuenced
aneurysm formation and progression in the elastase model of AAA
disease. Unexpectedly we experienced early ruptures in almost 50%
of the anti IL-6 treated animals, a notable phenomenon since, to the
best of our knowledge ruptures have not been described for the
elastase model. The aggravation of acute tissue damage during IL-6
neutralization proofs the efﬁcacy of the antibody used, but also ﬁts
in other reports showing that IL-6 is protective in the acute phases
of ischemia reperfusion injury and ischemia [34e37]. Yet, it is
obviously unclear how whether and how these experimental
ﬁndings from an acute model translate to the process of AAA for-
mation in man i.e. whether IL-6 has a role in protecting against AAA
formation.
We therefore performed a second series of experiments with
delayed anti-IL-6 therapy started at day 4 after the elastase treat-
ment. Delayed IL-6 neutralization did not result in ruptures, sug-
gesting that the deleterious effects of IL-6 inhibition relate to
processes involved in the initiation process of AAA formation in the
elastasemodel. Delayed therapy did result in a signiﬁcant reduction
of aneurysm progression.
A critical question is whether these mouse observations trans-
late to the human context. Although the acute aortic ruptures
observed in this study may not appear relevant for human AAA,
diverticular perforations have been observed during treatment
with Tocilizumab, a monoclonal antibody targeting the IL-6 re-
ceptor [11]. As such it cannot be excluded that IL-6 neutralization
may negatively affect clinical AAA disease. Data from the experi-
ments with delayed therapy hint at a beneﬁcial effect of IL-6
neutralization on AAA progression. A critical question is whether
quenching IL-6 has beneﬁcial effect in the clinical context. Our
earlier studies show that statins, ACE-inhibitors and doxycycline
therapy all profoundly reduce aneurysmwall IL-6 levels [15,38,39],
yet this is not followed by attenuation of aneurysm progression [4].
Although one could argue that halving IL-6 hyper-expression in
AAA disease is not sufﬁcient to interfere with AAA progression, it
remains to be established whether a further suppression is clini-
cally feasible. In fact, the observed accelerated aneurysm growth in
patients receiving doxycycline-treatment may (partially) relate to a
reduction in SOCS-1 expression in patients receiving doxycycline
and/or a role of IL-6 in tissue remodeling [40].In conclusion, this study conﬁrms exaggerated IL-6 levels and IL-
6 signaling in AAA disease, and although indications were found for
a beneﬁcial effect of AAA neutralization in the elastase model of
AAA disease, we also found indications for potential detrimental
effects. Moreover, indirect interference with aneurysm wall IL-6
content in clinical studies is not followed by a reduction in AAA
progression. As such this study does not identify IL-6 as a key-
driver of AAA progression, yet the data does not rule out a role
for IL-6 in AAA formation.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding conﬂict of interest with respect to this manuscript.
References
[1] A.T. Hirsch, Z.J. Haskal, N.R. Hertzer, et al., ACC/AHA 2005 Practice Guidelines
for the management of patients with peripheral arterial disease (lower ex-
tremity, renal, mesenteric, and abdominal aortic, Circulation 113 (2006)
e463ee654.
[2] D. Epstein, M.J. Sculpher, J.T. Powell, S.G. Thompson, L.C. Brown,
R.M. Greenhalgh, Long-term cost-effectiveness analysis of endovascular
versus open repair for abdominal aortic aneurysm based on four randomized
clinical trials, Br. J. Surg. 101 (2014) 623e631.
[3] B.T. Baxter, M.C. Terrin, R.L. Dalman, Medical management of small abdominal
aortic aneurysms, Circulation 117 (2008) 1883e1889.
[4] V.B. Kokje, J.F. Hamming, J.H. Lindeman, Editor’s choice e pharmaceutical
management of small abdominal aortic aneurysms: a systematic review of the
clinical evidence, Eur. J. Vasc. Endovasc. Surg. 50 (2015) 702e713.
[5] C.A. Meijer, T. Stijnen, M.N. Wasser, J.F. Hamming, J.H. van Bockel,
J.H. Lindeman, Doxycycline for stabilization of abdominal aortic aneurysms: a
randomized trial, Ann. Intern. Med. 159 (2013) 815e823.
[6] H. Sillesen, N. Eldrup, R. Hultgren, J. Lindeman, K. Bredahl, M. Thompson,
A. Wanhainen, U. Wingren, J. Swedenborg, Randomized clinical trial of mast
cell inhibition in patients with a medium-sized abdominal aortic aneurysm,
Br. J. Surg. 102 (2015) 894e901.
[7] J.H. Lindeman, H. Abdul-Hussien, A.F. Schaapherder, J.H. van Bockel, J.H. Von
der Thusen, D.L. Roelen, R. Kleemann, Enhanced expression and activation of
pro-inﬂammatory transcription factors distinguish aneurysmal from athero-
sclerotic aorta: IL-6- and IL-8-dominated inﬂammatory responses prevail in
the human aneurysm, Clin. Sci. Lond. 114 (2008) 687e697.
[8] L. Smallwood, R. Allcock, B.F. van, N. Warrington, L.J. Palmer, B. Iacopetta,
P.E. Norman, Polymorphisms of the interleukin-6 gene promoter and
abdominal aortic aneurysm, Eur. J. Vasc. Endovasc. Surg. 35 (2008) 31e36.
[9] M. Mihara, M. Hashizume, H. Yoshida, M. Suzuki, M. Shiina, IL-6/IL-6 receptor
system and its role in physiological and pathological conditions, Clin. Sci.
Lond. 122 (2012) 143e159.
[10] C.G. Santos-Gallego, B. Picatoste, J.J. Badimon, Pathophysiology of acute cor-
onary syndrome, Curr. Atheroscler. Rep. 16 (2014) 401.
[11] T. Gout, A.J. Ostor, M.K. Nisar, Lower gastrointestinal perforation in rheuma-
toid arthritis patients treated with conventional DMARDs or tocilizumab: a
systematic literature review, Clin. Rheumatol. 30 (2011) 1471e1474.
[12] J. Scheller, A. Chalaris, D. Schmidt-Arras, S. Rose-John, The pro- and anti-
inﬂammatory properties of the cytokine interleukin-6, Biochim. Biophys.
Acta 1813 (2011) 878e888.
[13] J.A. Fontes, N.R. Rose, D. Cihakova, The varying faces of IL-6: from cardiac
protection to cardiac failure, Cytokine 74 (2015) 62e68.
[14] H. Abdul-Hussien, R.G. Soekhoe, E. Weber, J.H. Von der Thusen, R. Kleemann,
A. Mulder, J.H. van Bockel, R. Hanemaaijer, J.H. Lindeman, Collagen degrada-
tion in the abdominal aneurysm: a conspiracy of matrix metalloproteinase
and cysteine collagenases, Am. J. Pathol. 170 (2007) 809e817.
[15] J.H. Lindeman, H. Abdul-Hussien, J.H. van Bockel, R. Wolterbeek, R. Kleemann,
Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in pa-
tients with an abdominal aneurysm: doxycycline selectively depletes aortic
wall neutrophils and cytotoxic T cells, Circulation 119 (2009) 2209e2216.
[16] R. Kleemann, P.P. Gervois, L. Verschuren, B. Staels, H.M. Princen, T. Kooistra,
Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in
hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex for-
mation, Blood 101 (2003) 545e551.
[17] J. Azuma, T. Asagami, R. Dalman, P.S. Tsao, Creation of murine experimental
abdominal aortic aneurysms with elastase, J. Vis. Exp. 29 (2009) 1280.
[18] R. Hurks, I.E. Hoefer, A. Vink, J.P. de Vries, R.H. Heijmen, A.H. Schoneveld,
M. Kerver, G. Pasterkamp, F.L. Moll, Aneurysm-express: human abdominal
aortic aneurysm wall expression in relation to heterogeneity and vascular
events e rationale and design, Eur. Surg. Res. 45 (2010) 34e40.
[19] D.A. Vignali, Multiplexed particle-based ﬂow cytometric assays, J. Immunol.
Methods 243 (2000) 243e255.
[20] W. de Jager, H. te Velthuis, B.J. Prakken, W. Kuis, G.T. Rijkers, Simultaneous
detection of 15 human cytokines in a single sample of stimulated peripheral
V.B.C. Kokje et al. / Atherosclerosis 251 (2016) 139e146146blood mononuclear cells, Clin. Diagn. Lab. Immunol. 10 (2003) 133e139.
[21] V. Treska, J. Kocova, L. Boudova, P. Neprasova, O. Topolcan, L. Pecen, Z. Tonar,
Inﬂammation in the wall of abdominal aortic aneurysm and its role in the
symptomatology of aneurysm, Cytokines Cell Mol. Ther. 7 (2002) 91e97.
[22] A.R. Brasier, The nuclear factor-kappaB-interleukin-6 signalling pathway
mediating vascular inﬂammation, Cardiovasc. Res. 86 (2010) 211e218.
[23] A.L. Golledge, P. Walker, P.E. Norman, J. Golledge, A systematic review of
studies examining inﬂammation associated cytokines in human abdominal
aortic aneurysm samples, Dis. Markers 26 (2009) 181e188.
[24] R.W. Thompson, P.J. Geraghty, J.K. Lee, Abdominal aortic aneurysms: basic
mechanisms and clinical implications, Curr. Probl. Surg. 39 (2002) 110e230.
[25] J.A. Curci, R.W. Thompson, Adaptive cellular immunity in aortic aneurysms:
cause, consequence, or context? J. Clin. Investig. 114 (2004) 168e171.
[26] Z. Szekanecz, M.R. Shah, W.H. Pearce, A.E. Koch, Human atherosclerotic
abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-
gamma but not IL-2 and IL-4: the possible role for IL-6 and interferon-
gamma in vascular inﬂammation, Agents Actions 42 (1994) 159e162.
[27] S.C. Harrison, A.J. Smith, G.T. Jones, et al., Interleukin-6 receptor pathways in
abdominal aortic aneurysm, Eur. Heart J. 34 (2012) 3707e3716.
[28] D.J. Parry, H.S. Al-Barjas, L. Chappell, S.T. Rashid, R.A. Ariens, D.J. Scott, Markers
of inﬂammation in men with small abdominal aortic aneurysm, J. Vasc. Surg.
52 (2010) 145e151.
[29] L.E. Rohde, L.H. Arroyo, N. Rifai, M.A. Creager, P. Libby, P.M. Ridker, R.T. Lee,
Plasma concentrations of interleukin-6 and abdominal aortic diameter among
subjects without aortic dilatation, Arterioscler. Thromb. Vasc. Biol. 19 (1999)
1695e1699.
[30] J. Dawson, G.W. Cockerill, E. Choke, A.M. Belli, I. Loftus, M.M. Thompson, Aortic
aneurysms secrete interleukin-6 into the circulation, J. Vasc. Surg. 45 (2007)
350e356.
[31] J.J. Babon, N.A. Nicola, The biology and mechanism of action of suppressor of
cytokine signaling 3, Growth Factors 30 (2012) 207e219.
[32] R. Eulenfeld, A. Dittrich, C. Khouri, P.J. Muller, B. Mutze, A. Wolf, F. Schaper,
Interleukin-6 signalling: more than Jaks and STATs, Eur. J. Cell Biol. 91 (2012)
486e495.[33] B.M. Zhu, Y. Ishida, G.W. Robinson, M. Pacher-Zavisin, A. Yoshimura,
P.M. Murphy, L. Hennighausen, SOCS3 negatively regulates the gp130-STAT3
pathway in mouse skin wound healing, J. Investig. Dermatol. 128 (2008)
1821e1829.
[34] D.K. de Vries, J.H. Lindeman, D. Tsikas, H.E. de, A. Roos, J.W. de Fijter,
A.G. Baranski, P.J. van, A.F. Schaapherder, Early renal ischemia-reperfusion
injury in humans is dominated by IL-6 release from the allograft, Am. J.
Transpl. 9 (2009) 1574e1584.
[35] L. Guidi, A. Tricerri, M. Costanzo, E. Adducci, M. Ciarniello, A.R. Errani, C.G. De,
P. Barattini, D. Frasca, C. Bartoloni, G. Nuzzo, G. Gasbarrini, Interleukin-6
release in the hepatic blood outﬂow during normothermic liver ischaemia in
humans, Dig. Liver Dis. 35 (2003) 409e415.
[36] T. Yamashita, K. Sawamoto, S. Suzuki, N. Suzuki, K. Adachi, T. Kawase,
M. Mihara, Y. Ohsugi, K. Abe, H. Okano, Blockade of interleukin-6 signaling
aggravates ischemic cerebral damage in mice: possible involvement of Stat3
activation in the protection of neurons, J. Neurochem. 94 (2005) 459e468.
[37] C.G. Santos-Gallego, T.P. Vahl, G. Goliasch, B. Picatoste, T. Arias, K. Ishikawa,
I.U. Njerve, J. Sanz, J. Narula, P.P. Sengupta, R.J. Hajjar, V. Fuster, J.J. Badimon,
Sphingosine-1-phosphate receptor agonist ﬁngolimod increases myocardial
salvage and decreases adverse postinfarction left ventricular remodeling in a
porcine model of ischemia/reperfusion, Circulation 133 (2016) 954e966.
[38] E. van der Meij, G.G. Koning, P.W. Vriens, M.F. Peeters, C.A. Meijer,
K.E. Kortekaas, R.L. Dalman, J.H. van Bockel, R. Hanemaaijer, T. Kooistra,
R. Kleemann, J.H. Lindeman, A clinical evaluation of statin pleiotropy: statins
selectively and dose-dependently reduce vascular inﬂammation, PLoS One 8
(2013) e53882.
[39] K.E. Kortekaas, C.A. Meijer, J.W. Hinnen, R.L. Dalman, B. Xu, J.F. Hamming,
J.H. Lindeman, ACE inhibitors potently reduce vascular inﬂammation, results
of an open proof-of-concept study in the abdominal aortic aneurysm, PLoS
One 9 (2014) e111952.
[40] S. Ray, X. Ju, H. Sun, C.C. Finnerty, D.N. Herndon, A.R. Brasier, The IL-6 trans-
signaling-STAT3 pathway mediates ECM and cellular proliferation in ﬁbro-
blasts from hypertrophic scar, J. Investig. Dermatol. 133 (2013) 1212e1220.
